<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04922658</url>
  </required_header>
  <id_info>
    <org_study_id>HMPL-012-SPRING-L106</org_study_id>
    <nct_id>NCT04922658</nct_id>
  </id_info>
  <brief_title>Surufatinib or Surufatinib Combined With Vinorelbine for Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Phase II, Single-arm, Two-cohorts, Open-label, Single Center Study of Surufatinib or Surufatinib Combined With Vinorelbine as Third-line and Posterior Line Treatment in Patients With Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase II study to assess the efficacy and safety of Surufatinib or Surufatinib combined&#xD;
      with Vinorelbine as third-line and posterior line treatment in patients with NSCLC&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>To assess the efficacy of Surufatinib or Surufatinib Combined With Vinorelbine for NSCLC , patients by assessment of progression free survival (PFS) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>CR + PR rate according to the RECIST version 1.1 guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>up to 12 months</time_frame>
    <description>CR + PR + SD rate according to the RECIST version 1.1 guidelines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>up to 36 months</time_frame>
    <description>The time interval between the start date of study drug and the date of death (any cause)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Advanced Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Surufatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Surufatinib plus Vinorelbine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surufatinib</intervention_name>
    <description>Surufatinib,250mg ,qd,po, 21 days for a cycle; continuous administration until PD, death or intolerable toxicity.</description>
    <arm_group_label>Surufatinib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surufatinib Plus Vinorelbine</intervention_name>
    <description>Surufatinib,250mg ,qd,po; Plus Vinorelbine, 60 mg / m2 BSA, d1, d8, d15; 21days for a cycle; continuous administration until PD, death or intolerable toxicity.</description>
    <arm_group_label>Surufatinib plus Vinorelbine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of written Informed Consent Form (ICF) prior to any study specific&#xD;
             procedures&#xD;
&#xD;
          2. Age ≥ 18 years, ≤80 years&#xD;
&#xD;
          3. Histologically or cytologically confirmed advanced NSCLC&#xD;
&#xD;
          4. At least two or more systemic therapies prior treatment of cytotoxic chemotherapy,&#xD;
             treatment failure or intolerable toxicities&#xD;
&#xD;
          5. ECOG 0-2&#xD;
&#xD;
          6. Patients must have measurable lesions&#xD;
&#xD;
          7. Expected overall survival ≥6 months&#xD;
&#xD;
          8. AST, ALT and alkaline phosphatase ≤ 2.5 times the upper limit of normal (ULN)，Serum&#xD;
             bilirubin ≤ 1.5 x ULN，creatinine&lt;ULN&#xD;
&#xD;
          9. Prothrombin time (PT), international standard ratio (INR) ≤1.5 × ULN&#xD;
&#xD;
         10. Women of childbearing age must be willing to use adequate contraceptives during the&#xD;
             study period of drug treatment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients have received Surufatinib treatment&#xD;
&#xD;
          2. Patients with small cell lung cancer (including mixed small cell lung cancer and&#xD;
             non-small cell lung cancer)&#xD;
&#xD;
          3. EGFR mutation /ALK rearrangement positive but not using relevant targeted drugs&#xD;
&#xD;
          4. Central squamous cell carcinoma with cavity or non-small cell lung cancer with&#xD;
             hemoptysis (&gt; 50 ml / D)&#xD;
&#xD;
          5. Have received other systemic anti-tumor therapies within 2 weeks before&#xD;
             recruited(eg.chemotherapy or radiotherapy, immunotherapy, biological or hormonal&#xD;
             therapy, or any VEGFR inhibitor treatment)&#xD;
&#xD;
          6. Participated in the clinical trials of other drugs that have not been approved or&#xD;
             marketed in China and received the corresponding experimental drug treatment within 2&#xD;
             weeks before enrollment&#xD;
&#xD;
          7. systolic blood pressure &gt; 140mmHg or diastolic blood pressure &gt; 90mmHg regardless of&#xD;
             any antihypertensive drugs; Or patients need more than two antihypertensive drugs&#xD;
&#xD;
          8. Clinically significant electrolyte abnormality&#xD;
&#xD;
          9. Proteinuria ≥ 2+ (1.0g/24hr)&#xD;
&#xD;
         10. Patients have untreated central nervous system metastasis&#xD;
&#xD;
         11. Received any operation or invasive treatment or operation (except venous&#xD;
             catheterization, puncture and drainage, etc.) within 4 weeks before enrollment&#xD;
&#xD;
         12. Patients have not recovered from all toxicities associated with prior anti-tumor&#xD;
             therapy ,to acceptable baseline status, or a National Cancer Institute Common&#xD;
             Terminology Criteria for Adverse Events(NCI CTCAE v5.0) Grade of 0 or 1, except for&#xD;
             alopecia and oxaliplatin induced neurotoxicity ≤ 2 , and the previous surgery did not&#xD;
             recover completely&#xD;
&#xD;
         13. Dysphagia or known malabsorption of drugs&#xD;
&#xD;
         14. Active gastric and duodenal ulcer, ulcerative colitis or uncontrolled hemorrhage in GI&#xD;
&#xD;
         15. Have evidence or history of bleeding tendency within 2 months after enrollment, the&#xD;
             researcher assessed that moderate or severe bleeding tendency was not suitable for&#xD;
             enrollment&#xD;
&#xD;
         16. Patients had other malignant tumors in the past 5 years or at the same time (except&#xD;
             for the cured skin basal cell carcinoma and cervical carcinoma in situ);&#xD;
&#xD;
         17. Pregnant or lactating women&#xD;
&#xD;
         18. Allergic to Surufatinib/Vinorelbine&#xD;
&#xD;
         19. History of immunodeficiency, including HIV positive, other acquired or congenital&#xD;
             immunodeficiency diseases, or organ transplantation&#xD;
&#xD;
         20. Patients with acute myocardial infarction, severe / unstable angina pectoris or&#xD;
             coronary artery bypass grafting within 6 months before admission; Or a history of&#xD;
             arterial thrombosis or deep venous thrombosis&#xD;
&#xD;
         21. There are concomitant diseases (such as severe hypertension, diabetes, thyroid&#xD;
             disease, active infection, etc.) that seriously endanger the safety of patients or&#xD;
             affect the completion of the study, or any laboratory abnormalities that are not&#xD;
             suitable for participating in the clinical trial according to the judgment of the&#xD;
             researcher&#xD;
&#xD;
         22. Serious psychological or mental disorders that may affect the compliance study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanfang Zheng, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yanfang Zheng, M.D., Ph.D.</last_name>
    <phone>86-18665000236</phone>
    <email>18665000236@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Affiliated Cancer Hospital and Institute of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510095</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 6, 2021</study_first_submitted>
  <study_first_submitted_qc>June 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2021</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

